At a glance
ClinicalIndex Comparison RecordN/ACompleted· 714 enrolled
Drug / intervention
Fluciclovine (18F)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects
In Brief
An observational study evaluating Fluciclovine (18F) for Prostatic Neoplasms. Completed, enrolled 714 participants across 4 sites in 3 countries.
Detailed Summary
This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms
CountriesItaly, Norway, United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedMay 2015
Primary CompletionJun 2015
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartJan 1, 2015
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.1 years ago
Interventions
Fluciclovine (18F)radiation
Not applicable. This is an observational study.